Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer

被引：0
|
作者：
Hudes, G. R.
Nanus, D.
Qi, M.
Prabhakar, U.
Corringham, R.
Jiao, Q.
Eisenberger, M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Cornell Univ, New York Presbyterian Hosp, New York, NY 10021 USA
[3] Centocor Inc, Malvern, PA 19355 USA
[4] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15521
引用
收藏
页数：2
相关论文
共 50 条
  • [31] DOCETAXEL AND ZOLEDRONIC ACID COMBINATION ADMINISTERED IN TWO DIFFERENT SEQUENCES IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS: PHASE I CLINICAL STUDY - ZANTE
    Facchini, G.
    Caraglia, M.
    Morabito, A.
    Bruni, S. G.
    Nasti, G.
    Maiolino, P.
    Striano, S.
    Budillon, A.
    Di Napoli, A.
    Marra, M.
    Pisano, C.
    Pignata, S.
    Perrone, F.
    Iaffaioli, R. V.
    EJC SUPPLEMENTS, 2008, 6 (14): : 124 - 124
  • [32] Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
    Fleming, Mark T.
    Rathkopf, Dana E.
    Gibbons, Jackie
    Peterson, Amy C.
    Hannah, Alison
    Forer, David
    Scher, Howard I.
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Docetaxel and Curcuminoids Combination In Patients With Hormone Resistant Prostate Cancer - a Phase II Study
    Mahammedi, H.
    Planchat, E.
    Durando, X.
    Barthomeuf, C.
    Bayet-Robert, M.
    Van-Praagh, I.
    Francannet, P.
    Guy, L.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S498 - S498
  • [34] Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (MAb), in patients with renal cell carcinoma (RCC).
    Jang, H
    Prabhakar, U
    Jiao, Q
    Ford, J
    Miller, BE
    Davis, HM
    Graham, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 189S - 189S
  • [35] A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
    Gary Hudes
    Scott T. Tagawa
    Young E. Whang
    Ming Qi
    Xiang Qin
    Thomas A. Puchalski
    Manjula Reddy
    Mark Cornfeld
    Mario Eisenberger
    Investigational New Drugs, 2013, 31 : 669 - 676
  • [36] A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
    Hudes, Gary
    Tagawa, Scott T.
    Whang, Young E.
    Qi, Ming
    Qin, Xiang
    Puchalski, Thomas A.
    Reddy, Manjula
    Cornfeld, Mark
    Eisenberger, Mario
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 669 - 676
  • [37] Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer
    Wilding, G
    Soulie, P
    Trump, D
    Das-Gupta, A
    Small, E
    CANCER, 2006, 106 (09) : 1917 - 1924
  • [38] A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Ryan, CW
    Stadler, WM
    Vogelzang, NJ
    BJU INTERNATIONAL, 2005, 95 (07) : 963 - 968
  • [39] Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
    J Carles
    A Font
    B Mellado
    M Domenech
    E Gallardo
    J L González-Larriba
    G Catalan
    J Alfaro
    A Gonzalez del Alba
    M Nogué
    P Lianes
    J M Tello
    British Journal of Cancer, 2007, 97 : 1206 - 1210
  • [40] A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC).
    Oh, WK
    Hagmann, E
    Manola, J
    George, DJ
    Gilligan, TD
    Smith, MR
    Kaufman, DS
    Kantoff, PW
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 420S - 420S
12345